Our Authors
Bill Petch is the Co-Chair of All.Can Australia and former CEO of the Leukaemia Foundation. Bill is a strong advocate for improving patient outcomes and delivering care of value to the cancer community, and believes that technology has a crucial role to play in this.1 Articles
Professor Andrew Scott is a nuclear medicine physician and a scientist and researcher, who sees oncology patients as part of therapeutics development and clinical trials. He is the Director of Molecular Imaging and Therapy, Austin Health where his team are pioneering new imaging technologies that promise to transform the diagnosis of multiple cancers. In addition to his work at Austin Health and academic roles, he leads the Tumour Targeting Laboratory in the Olivia Newton-John Cancer Research Institute. He has been working in the area of molecular imaging and new diagnostics and therapeutics for over 20 years.1 Articles
The leading lung cancer & mesothelioma clinical trials group in Australia & New Zealand1 Articles
Professor Martin Tattersall AO (Vale) was a true giant in Australian medical oncology. His achievements and legacy will continue to reverberate through the oncology sphere for many decades to come. He authored almost 600 papers, was a founding member of MOGA, a beloved teacher and mentor, held vital roles in myriad committees and working groups, and won multiple awards. He was also an exceptionally gifted, compassionate and kind physician who's efforts provided great comfort to patients, their families and friends. For more in-depth obituaries, see the MOGA and Cancer Council websites.1 Articles
Prof. Christobel Saunders, All.Can Australia Steering Committee member, Prof. Surgical Oncology University of Western Australia and in-coming James Stewart Chair of Surgery Royal Melbourne Hospital1 Articles
Jane M Ussher is Professor of Women’s Health Psychology, in the Translational Health Research Institute, at Western Sydney University. Her research focuses on sexual and reproductive embodiment, and the gendered experience of cancer and cancer care. As a trained clinical psychologist, she has also made a contribution to the integration of research and clinical practice in gendered health, and has developed and evaluated a number of psycho-educational interventions in the field of cancer care. This includes resources to address sexual changes after cancer, fertility concerns, and the needs of cancer carers, funded by the Australian Research Council (ARC) in collaboration with Cancer Council NSW. Jane is author of over 300 papers and chapters, 12 books, and is editor of the Routledge Women and Psychology book series. She has received over $10M in research funding, and was awarded the Steven Grunberg Memorial Award, at the MASCC (Multinational Association of Supportive Care in Cancer) annual conference in 2019 for her research on gay and bisexual men’s experiences of prostate cancer. She is leading an ARC Linkage funded research study, on LGBTQI+ experiences of cancer, in collaboration with The Cancer Council NSW, Prostate Cancer Foundation, National LGBT Health Alliance, ACON, Breast Cancer Network Australia, Sydney Children's Hospital Network and Canteen. The study includes a survey, interviews and photo elicitation with LGBTQI+ cancer survivors and their carers, a survey of oncology health care professionals, and an audit of cancer guidelines. The findings will be translated into resources for LGBTQI+ cancer survivors and their carers, as well as practice and policy guidelines.1 Articles
Professor Nat Lenzo is a Nuclear Medicine and Internal Medicine Physician and the Medical Director of Theranostics at GenesisCare. From 2001-2006, Nat was the inaugural head of the Western Australia PET/cyclotron service based at Sir Charles Gardiner Hospital. In 2015, Nat founded Theranostics Australia which became part of GenesisCare in 2017 to complement GenesisCare’s radiation oncology services to cancer patients in Australia and internationally. The GenesisCare Theranostics team is committed to developing and using targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers, with a focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. With a strong track record in developing clinical and research services in the public and private sectors, Nat’s research interests are in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. He is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and a co-author on over 80 peer reviewed publications, predominantly in the areas of molecular imaging and therapy in neuroscience and oncology.1 Articles
Henry Woo is a urological surgeon who subspecialises in prostate disease. e is the Director of Uro-Oncology and Professor of Robotic Cancer Surgery at the Chris O’Brien Lifehouse. He is also Professor of Surgery at the Sydney Adventist Hospital Clinical School of the University of Sydney. He has published widely in major urological journals. He is an Associate Editor of the journal Prostate Cancer Prostatic Diseases and serves on the journal editorial boards of European Urology, BJUI, Prostate International, Asian Journal of Urology and World Journal of Men’s Health. He also serves on the board of the charitable Australian Urological Foundation(AUF) and is a member of the Executive Committee of the Asian Pacific Prostate Society (APPS). He is passionate about clinical trials and procuring the best evidenced based options for his patients. He also has particular interests in surgical education and the role of social media in learning and health advocacy1 Articles